Ark Therapeutics Group plc (‘Ark’) today announces further positive results from a Phase II trial of Trinam(R), its novel gene therapy to prevent blood vessels blocking in kidney dialysis patients who have undergone vascular access graft surgery. Results of the low dose group were first reported in October 2005. The new data show that the access grafts of low dose patients remain functional for dialysis on average over five times longer (17.8 months) than control patients in the trial (3.3 months). In the high dose group, recruited after the low dose group, all patients with successful graft implants still have open grafts with patency averaging 8 months so far. For the primary end point of safety, no systemic distribution of Trinam(R) has been found in either of the high or low dose groups and the product is well tolerated.
